NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and G…
Medical - Instruments & Supplies
JE, Saint Helier [HQ]
NVCR/Financial Reporting
Income Statements
11 Sheets · Starting from 2013In Million USD. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00 | 15.00 | 33.00 | 82.00 | 177.00 | 248.00 | 351.00 | 494.00 | 535.00 | 537.00 | 509.00 | |
|
EPS
|
-1.07 | -1.12 | -3.67 | -1.54 | -0.70 | -0.69 | -0.07 | 0.20 | -0.56 | -0.88 | -1.95 | |
| Diluted in mil. | -1.07 | -1.12 | -3.67 | -1.54 | -0.70 | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | |
|
Profit
|
3.00 | 5.00 | 12.00 | 36.00 | 121.00 | 168.00 | 262.00 | 387.00 | 420.00 | 422.00 | 381.00 | |
| Gross Margin | 32.30 | 35.21 | 37.71 | 44.16 | 68.59 | 67.73 | 74.78 | 78.46 | 78.53 | 78.64 | 74.81 | |
| Pre Tax | -77.00 | -80.00 | -107.00 | -121.00 | -48.00 | -45.00 | -8.00 | 18.00 | -52.00 | -81.00 | -191.00 | |
| Profit Margin | -743.48 | -518.40 | -323.83 | -146.54 | -27.40 | -18.52 | -2.51 | 3.66 | -9.73 | -15.22 | -37.64 | |
| ETR | -0.46 | -0.48 | -4.14 | -8.55 | -27.15 | -38.35 | 18.06 | -9.42 | -12.05 | -13.06 | -7.98 | |
| Net | -77.00 | -80.00 | -111.00 | -131.00 | -61.00 | -63.00 | -7.00 | 19.00 | -58.00 | -92.00 | -207.00 | |
| Profit Margin | -746.89 | -520.87 | -337.24 | -159.06 | -34.83 | -25.62 | -2.06 | 4.01 | -10.91 | -17.20 | -40.65 | |
| EBITDA | -68.00 | -78.00 | -103.00 | -115.00 | -39.00 | -33.00 | - - | 30.00 | -44.00 | -89.00 | -176.00 | |
| EBITDA Margin | -661.13 | -504.80 | -314.31 | -139.12 | -22.22 | -13.57 | -0.26 | 6.15 | -8.29 | -16.64 | -34.68 | |
| Operating Income | -64.00 | -80.00 | -103.00 | -115.00 | -39.00 | -33.00 | - - | 21.00 | -44.00 | -89.00 | -232.00 | |
| Operating Margin | -622.25 | -517.47 | -314.31 | -139.12 | -22.22 | -13.57 | -0.26 | 4.30 | -8.29 | -16.64 | -45.72 | |
| Interest Income | - - | - - | - - | - - | 1.00 | 2.00 | 4.00 | 1.00 | - - | 10.00 | 19.00 | |
| Loss | -74.00 | -95.00 | -137.00 | -198.00 | -216.00 | -281.00 | -352.00 | -463.00 | -579.00 | -627.00 | -742.00 | |
| Cost of Revenue | -7.00 | -10.00 | -20.00 | -46.00 | -55.00 | -80.00 | -88.00 | -106.00 | -114.00 | -114.00 | -128.00 | |
|
Operating Expenses
|
-67.00 | -85.00 | -116.00 | -151.00 | -160.00 | -201.00 | -263.00 | -357.00 | -464.00 | -512.00 | -613.00 | |
| R&D | -34.00 | -40.00 | -43.00 | -41.00 | -38.00 | -50.00 | -79.00 | -132.00 | -201.00 | -206.00 | -223.00 | |
| G&A | -16.00 | -24.00 | -33.00 | -51.00 | -59.00 | -73.00 | -87.00 | -107.00 | -126.00 | -132.00 | -164.00 | |
| SG&A | -33.00 | -45.00 | -72.00 | -110.00 | -122.00 | -151.00 | -184.00 | -225.00 | -263.00 | -306.00 | -390.00 | |
| S&M | -16.00 | -21.00 | -38.00 | -59.00 | -63.00 | -77.00 | -96.00 | -118.00 | -137.00 | -173.00 | -226.00 | |
| Depreciation and Amortization | -1.00 | -1.00 | -3.00 | -5.00 | -7.00 | -9.00 | -8.00 | -9.00 | -10.00 | -10.00 | -10.00 | |
| Interest Expenses | -7.00 | - - | -2.00 | -5.00 | -10.00 | -13.00 | -13.00 | -13.00 | -3.00 | -3.00 | -3.00 | |
| Other Expenses | - - | - - | - - | - - | - - | - - | -7.00 | -3.00 | -7.00 | -7.00 | - - | |
|
WA Shares Outstanding
|
72.00 | 72.00 | 30.00 | 85.00 | 88.00 | 91.00 | 97.00 | 100.00 | 103.00 | 104.00 | 106.00 | |
| Diluted | 72.00 | 72.00 | 30.00 | 85.00 | 88.00 | 91.00 | 97.00 | 108.00 | 103.00 | 104.00 | 106.00 |